Literature DB >> 11302687

Cell cycle regulation of NF-kappa b-binding activity in cells from human glioblastomas.

S A Ansari1, M Safak, L Del Valle, S Enam, S Amini, K Khalili.   

Abstract

Glioblastoma multiforme is a highly malignant and anaplastic tumor of the central nervous system representing more than 50% of all malignant gliomas. The cell origin of this highly undifferentiated tumor remains obscure, although it is postulated that glioblastomas are developed from astrocytes. The rapid growth of the glioma and the state of its undifferentiation are attributed to the deregulation of several signal transduction pathways and cell cycle events. Recent studies showed diverse functions for the NF-kappa B/Rel family of inducible transcription factors including differentiation, apoptosis, oncogenesis, and cell cycle regulation. We sought to examine the level of NF-kappa B activity throughout the glioma's cell cycle. Results from band-shift studies indicated a biphasic NF-kappa B DNA-binding activity in the nuclei of cycling glioblastoma cells. We showed that NF-kappa B-binding activity maximizes in nuclear extracts at specific cell cycle stages including G0/G1, mid-late G1, and S phase. Results from Northern blotting studies revealed that the differential expression of the NF-kappa B subunits, p50 and p65, may not be responsible for cell cycle stage-specific association of NF-kappa B subunits with DNA. However, results from Western blotting analysis utilizing nuclear extracts from glioma cells throughout the cell cycle demonstrated that the nuclear accumulation of p50 and p65 perfectly correlates with their DNA-binding activity. These observations suggest that the nuclear translocation of the p50/p65 subunit of NF-kappa B in glioma cells is cell cycle stage-dependent and that is distinct from the differential mRNA expression of these genes during glioma cell cycling. The possible role of NF-kappa B in glioma cell formation and regulation of cellular genes by NF-kappa B in these tumor cells is discussed. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302687     DOI: 10.1006/excr.2001.5168

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Functional interaction between JC virus late regulatory agnoprotein and cellular Y-box binding transcription factor, YB-1.

Authors:  Mahmut Safak; Beata Sadowska; Robert Barrucco; Kamel Khalili
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Phosphorylation mutants of JC virus agnoprotein are unable to sustain the viral infection cycle.

Authors:  Ilker K Sariyer; Ilhan Akan; Victoria Palermo; Jennifer Gordon; Kamel Khalili; Mahmut Safak
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.

Authors:  Gangadhara Reddy Sareddy; Khamushavalli Geeviman; Chinta Ramulu; Phanithi Prakash Babu
Journal:  J Neurooncol       Date:  2011-08-17       Impact factor: 4.130

4.  Withania somnifera Suppresses Tumor Growth of Intracranial Allograft of Glioma Cells.

Authors:  Hardeep Kataria; Sushil Kumar; Harshita Chaudhary; Gurcharan Kaur
Journal:  Mol Neurobiol       Date:  2015-07-26       Impact factor: 5.590

5.  An NF-κB- and Therapy-Related Regulatory Network in Glioma: A Potential Mechanism of Action for Natural Antiglioma Agents.

Authors:  Evrysthenis Vartholomatos; Stefania Mantziou; George A Alexiou; Diamanto Lazari; Chrissa Sioka; Athanassios Kyritsis; Georgios S Markopoulos
Journal:  Biomedicines       Date:  2022-04-19

6.  Critical parameters determining standard radiotherapy treatment outcome for glioblastoma multiforme: a computer simulation.

Authors:  D D Dionysiou; G S Stamatakos; D Gintides; N Uzunoglu; K Kyriaki
Journal:  Open Biomed Eng J       Date:  2008-09-10

7.  Infection by agnoprotein-negative mutants of polyomavirus JC and SV40 results in the release of virions that are mostly deficient in DNA content.

Authors:  Ilker K Sariyer; Abdullah S Saribas; Martyn K White; Mahmut Safak
Journal:  Virol J       Date:  2011-05-24       Impact factor: 4.099

8.  A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].

Authors:  Pierre A Robe; Didier Martin; Adelin Albert; Manuel Deprez; Alain Chariot; Vincent Bours
Journal:  BMC Cancer       Date:  2006-01-31       Impact factor: 4.430

9.  The Curcumin Analog C-150, Influencing NF-κB, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo.

Authors:  László Hackler; Béla Ózsvári; Márió Gyuris; Péter Sipos; Gabriella Fábián; Eszter Molnár; Annamária Marton; Nóra Faragó; József Mihály; Lajos István Nagy; Tibor Szénási; Andrea Diron; Árpád Párducz; Iván Kanizsai; László G Puskás
Journal:  PLoS One       Date:  2016-03-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.